title: Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.
abstract: Extracellular adenosine is a potent immunosuppressor that accumulates during tumor growth. We performed proof-of-concept studies investigating the therapeutic potential and mechanism of action of monoclonal antibody (mAb)-based therapy against CD73, an ecto-enzyme overexpressed on breast-cancer cells that catalyzes the dephosphorylation of adenosine monophosphates into adenosine. We showed that anti-CD73 mAb therapy significantly delayed primary 4T1.2 and E0771 tumor growth in immune-competent mice and significantly inhibited the development of spontaneous 4T1.2 lung metastases. Notably, anti-CD73 mAb therapy was essentially dependent on the induction of adaptive anti-tumor immune responses. Knockdown of CD73 in 4T1.2 tumor cells confirmed the tumor-promoting effects of CD73. In addition to its immunosuppressive effect, CD73 enhanced tumor-cell chemotaxis, suggesting a role for CD73-derived adenosine in tumor metastasis. Accordingly, administration of adenosine-5'-N-ethylcarboxamide to tumor-bearing mice significantly enhanced spontaneous 4T1.2 lung metastasis. Using selective adenosine-receptor antagonists, we showed that activation of A2B adenosine receptors promoted 4T1.2 tumor-cell chemotaxis in vitro and metastasis in vivo. In conclusion, our study identified tumor-derived CD73 as a mechanism of tumor immune escape and tumor metastasis, and it also established the proof of concept that targeted therapy against CD73 can trigger adaptive anti-tumor immunity and inhibit metastasis of breast cancer.
authors.affiliation: Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia. john.stagg@petermac.org
authors.forename: John
authors.initials: J
authors.lastname: Stagg
authors.forename: Upulie
authors.initials: U
authors.lastname: Divisekera
authors.forename: Nicole
authors.initials: N
authors.lastname: McLaughlin
authors.forename: Janelle
authors.initials: J
authors.lastname: Sharkey
authors.forename: Sandra
authors.initials: S
authors.lastname: Pommey
authors.forename: Delphine
authors.initials: D
authors.lastname: Denoyer
authors.forename: Karen M
authors.initials: KM
authors.lastname: Dwyer
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Smyth
mesh_terms: D015720:5'-Nucleotidase / Q000235:genetics / Q000276:immunology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000276:immunology* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D045744:Cell Line, Tumor; D002465:Cell Movement; D018450:Disease Progression; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D016513:Mice, SCID; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation
chemical_list: D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D015720:5'-Nucleotidase